NovellusDx Tissue Collection Protocol

Patients Eligible for Tumor Biopsy Clinical Trial

Official title:

An Observational Study to Assess the Oncogenic Status of Colorectal Cancer Patients That Have Undergone Surgery

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01791322
• Other study ID #: PM 01.1
• Status: Completed
• First received: February 12, 2013
• Last updated: March 27, 2018
• Start date: January 2014
• Est. completion date: June 2016

Study information

• Verified date: October 2015
• Source: NovellusDx
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

NovellusDx is developing a diagnostic platform for the personalized cancer therapy based on patient derived tumor tissue. The assay is able to sense activating mutations by monitoring their effect on a chip-based device.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 15
• Est. completion date: June 2016
• Est. primary completion date: June 2016
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 85 Years

Eligibility

Inclusion Criteria:

• Patients that have been diagnosed positive for colon cancer.

• available treatment follow up during cancer treatment

Exclusion Criteria:

Related Conditions & MeSH terms

• Colorectal Neoplasms
• Patients Eligible for Tumor Biopsy
• Patients That Have Been Diagnosed With Colorectal Cancer

Locations

Country	Name	City	State
Israel	Pathology Lab Hadassah Medical Center	Jerusalem

Sponsors (1)

Lead Sponsor	Collaborator
NovellusDx

Country where clinical trial is conducted

Israel, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Correct identification of tumor mutant genes	Correct identification of tumor mutant genes, in over 85% of the cases	up to 12 month